The Effects on Sperm Production from Lymphoma Treatment

A new study regarding spermatogenesis—the development of sperm cells within the male reproductive organs—reveals some startling things about the effects of lymphoma and its treatment on male fertility.

In this multicenter prospective longitudinal study, patients were analyzed before treatment and after at 3, 6, 12, and 24 months. A total of 75 patients with Hodgkin's or non-Hodgkin's lymphoma were recruited, along with a control group of 257 fertile men.

The study was conducted by Louis Bujan MD PhD from Universite de Toulouse in France and colleagues. They reported their results online in the journal Fertility and Sterility.

To begin, compared to the control group, altered sperm DNA and chromatin was more common among the lymphoma patients before treatment even began (chromatin is the DNA and proteins at the nucleus of a cell). Unfortunately, they didn't speculate on why this might be happening, or if it had anything to do with the cancer.

From there, the results were broken down by treatment:

  • ABVD chemotherapy or ABVD plus radiotherapy: Sperm count recovered to pre-treatment levels for most patients at around twelve months, and they estimate that 90 percent of these patients will return to normal sperm count.
  • CHOP chemotherapy and MOPP chemotherapy: Treatment was significantly harder on these patients, and the team could say only that about 61 percent of them would be expected to recover to pre-treatment sperm count.

After 24 months, sperm production recovers in male patients—but not in all of them. Seven percent of in the study were azoospermic after 24 months—meaning that no measurable sperm could be detected in their semen.

"These data on both the recovery period according to treatment modalities and the pre- and post-treatment chromatin status of sperm are useful tools for counseling patients wishing to conceive," they concluded.

Source: Fertility and Sterility

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap